Localized Delivery of Proteins in the Brain: Can Transport Be Customized?
- 1 March 1998
- journal article
- review article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 15 (3) , 377-385
Abstract
Certain central nervous system (CNS) diseases are characterized by the degeneration of specific cell populations. One strategy for treating neurodegenerative diseases is long-term, controlled...Keywords
This publication has 84 references indexed in Scilit:
- Engineering dynamics of growth factors and other therapeutic ligandsBiotechnology and Bioengineering, 1996
- Distribution of drugs following controlled delivery to the brain interstitiumJournal of Neuro-Oncology, 1995
- Differential distribution of exogenous BDNF, NGF, and NT‐3 in the brain corresponds to the relative abundance and distribution of high‐affinity and low‐affinity neurotrophin receptorsJournal of Comparative Neurology, 1995
- Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patientsNeuroscience Letters, 1994
- Polymer ConjugatesClinical Pharmacokinetics, 1994
- Brain interstitial volume fraction and tortuosity in anoxia. Evaluation of the ion‐selective micro‐electrode methodActa Physiologica Scandinavica, 1992
- Receptor‐mediated retrograde transport in CNS neurons after intraventricular administration of NGF and growth factorsJournal of Comparative Neurology, 1991
- Recombinant human nerve growth factor prevents retrograde degeneration of axotomized basal forebrain cholinergic neurons in the ratExperimental Neurology, 1991
- Diffusion of fluorescein‐labelled molecules in suspensions of erythrocyte ghostsFEBS Letters, 1988
- Treatment of Adenosine Deaminase Deficiency with Polyethylene Glycol–Modified Adenosine DeaminaseNew England Journal of Medicine, 1987